Scientists searching for new ways to treat ovarian cancer have identified two familiar cannabis compounds as promising candidates, offering a potential new avenue against one of the deadliest gynecological malignancies.
In laboratory experiments, researchers found that both THC, the psychoactive compound in cannabis, and CBD, a non-intoxicating cannabinoid, were able to slow the growth of ovarian cancer cells. When used together, the compounds were even more effective, stopping cancer cells from reproducing and, in some cases, killing them outright. The findings were published in the journal Frontiers in Pharmacology.
Ovarian cancer is notoriously difficult to detect early, and many patients are diagnosed only after the disease has spread. While chemotherapy and other treatments have improved outcomes for some, recurrence is common and drug resistance remains a major obstacle. As a result, researchers continue to look for therapies that are both more effective and less toxic than existing options.
“Our goal is to find alternative drugs that can improve efficacy and potentially reduce toxicity,” said Dr. Siyao Tong of Khon Kaen University, the study’s lead author. “Ovarian cancer remains one of the deadliest gynecological cancers, with limited effective treatment options.”
The research team tested THC and CBD on two different ovarian cancer cell lines — one sensitive to standard platinum-based chemotherapy and another resistant to it. In both cases, exposure to either compound reduced the cancer cells’ ability to survive and form new colonies. The most striking results came when the cannabinoids were combined.
“Notably, the inhibitory effect was most pronounced when CBD and THC were used in a 1:1 ratio,” Tong said, adding that the combination also limited the cancer cells’ ability to migrate, a key step in metastasis.
Importantly, the cannabinoids had minimal impact on healthy cells grown alongside the cancer lines, raising the possibility that future treatments could be easier for patients to tolerate than conventional chemotherapy.
Further analysis suggested that THC and CBD may work by restoring balance to a cell signaling pathway commonly overactive in ovarian cancer, known as PI3K/AKT/mTOR. Disrupting this pathway can prevent tumor growth and make cancer cells more vulnerable to treatment.
The researchers caution that the findings are still preliminary. All experiments were conducted in vitro, meaning in laboratory dishes rather than in living organisms. Animal studies and clinical trials will be needed to determine whether cannabinoid-based therapies are safe and effective for patients.
Still, Tong said the results provide a foundation for future work. If confirmed, cannabis-derived compounds could one day contribute to new, less toxic treatment strategies for a disease in urgent need of better options.
Read the whole article from Marijuanamoment here.
